Clinical Trials Browser

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03913923 2023-02-10

OBERTON

Phase 2 Unknown

117 enrolled

Dermatologic

Melanoma

NCT05051865 2022-11-17

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

Phase 2 Unknown

60 enrolled

Dermatologic

Melanoma

NCT02036086 2022-10-27

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Phase 2 Unknown

24 enrolled

Dermatologic

Melanoma

NCT04913025 2022-09-21

REFINE

Phase 2 Unknown

160 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT03780608 2022-06-15

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Phase 2 Unknown

61 enrolled

Dermatologic

Melanoma

NCT05104801 2021-11-04

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Phase 2 Unknown

37 enrolled

Dermatologic

Melanoma

NCT05097378 2021-10-28

PREMIUM

Phase 2 Unknown

45 enrolled

Dermatologic

Melanoma, Neoplasms

NCT03925350 2021-10-22

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Phase 2 Unknown

41 enrolled

Dermatologic

Melanoma

NCT04979585 2021-08-03

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

Phase 2 Unknown

66 enrolled

Dermatologic

Melanoma

NCT04928365 2021-06-16

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Phase 2 Unknown

50 enrolled

Dermatologic

Melanoma

NCT04884997 2021-05-13

A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma

Phase 2 Unknown

90 enrolled

Dermatologic

Melanoma

NCT03313323 2021-04-15

Zirconipi

Phase 2 Unknown

29 enrolled

Dermatologic

Melanoma

NCT02501551 2021-04-05

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Phase 2 Unknown

36 enrolled

Dermatologic

Melanoma

NCT02617849 2021-02-18

Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

Phase 2 Unknown

30 enrolled

Dermatologic

Melanoma

NCT04749485 2021-02-11

A Study of HX008 for the Treatment of Patients With Malignant Melanoma

Phase 2 Unknown

119 enrolled

Dermatologic

Melanoma

NCT04593485 2020-12-23

Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract

Phase 2 Unknown

40 enrolled

Dermatologic

Melanoma

NCT03013101 2020-09-30

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Phase 2 Unknown

128 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis

NCT03269565 2020-09-18

MIRACULUM

Phase 2 Unknown

126 enrolled

Dermatologic

Melanoma

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04397770 2020-05-21